[Development of pharmacologic criteria for development of antianginal medications].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy / Q000517:prevention & control*; D004357:Drug Synergism; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use; D013565:Sympatholytics / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D008996:Monoamine Oxidase Inhibitors; D013565:Sympatholytics; D014665:Vasodilator Agents; D005996:Nitroglycerin
Evolution des critères pharmacologiques pour le développement des medications antiangineuses.